IC-OS webinar: Immune Checkpoint Inhibitor Associated Myocarditis: Practical Evaluations

Dr Kearney is a post CCT fellow in cardio-oncology and cardiac imaging at St Bartholomew’s Hospital in London. She completed her medical school training at Queen’s University Belfast and her clinical training in cardiology in Northern Ireland.

Chiara Bucciarelli-Ducci is a cardiologist at Bristol Heart Institute, Bristol, UK.

Dr Lenihan has been active in cardio-oncology and heart failure, for over 20 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the Principal Investigator of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma and the recently completed PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. In addition, he is intimately involved in the latest treatment trials for cardiac amyloidosis. He was recently at Washington University in St Louis to enhance and expand the Cardio-Oncology Center of Excellence. He is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current President of the International Cardio-Oncology Society (ICOS),www.IC-OS.org, which is an international professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.

Lauren A. Baldassarre, MD is Associate Professor of Cardiovascular Medicine and Radiology & Biomedical Imaging at Yale School of Medicine in New Haven, CT. She is the Director of the Yale Smilow Cancer Center Cardio-Oncology Program and the Cardiology Director of Cardiac MR/CT for Yale New Haven Hospital. She is also the Program Director for the newly established Yale Cardio-Oncology Advanced Fellowship Program. Dr. Baldassarre is a member of the American College of Cardiology Cardio-Oncology Section Leadership Council and is the Chair of the International Cardio-Oncology Society Imaging Work Group. She is the Chair of the Society for Cardiovascular Magnetic Resonance Cardio-Oncology Special Interest Group and is a member of the Society of Cardiovascular Computed Tomography Cardio-Oncology Writing Group. Her clinical and research interests include the use of advanced multimodality cardiac imaging for the detection, management, and prevention of cardiotoxicity from cancer therapeutics.

Dr. Neilan received his M.D. from University College Dublin and MPH from Harvard School of Public Health. He completed internal medicine residency and cardiology training at the Mater Misericordiae Hospital in Dublin and again at Massachusetts General Hospital. He has also completed extensive training in echocardiography at Massachusetts General Hospital and cardiac magnetic resonance at the Brigham and Women's Hospital. Dr. Neilan is an Associate Professor of Medicine at Harvard Medical School, the Director of the Cardio-Oncology Program and the Co-Director of the Cardiac MR PET CT Program. Dr. Neilan has had a long-standing clinical and research interest in the cardiovascular care of patients with cancer. Cardiovascular disease is a leading cause of death and disability among cancer survivors and cardiovascular care for patients with cancer requires a tailored approach that is unique for each patient. He is specifically interested in how we can improve on the methods for detection of the cardiac toxicity after chemotherapy and radiotherapy and to use that information to determine how we care for patients.